C2 PHARMA brings reliable cannabidiol (cbd) api source to pharma companies and expands its r&d product pipeline

C2 PHARMA launches initiative to bring a reliable source of naturally
extracted GMP-compliant Cannabidiol (CBD) to pharmaceutical

  • In parallel, C2 PHARMA announces a major R&D program to bring 10
    new APIs into its product pipeline as well as three botanical extracts for
    pharmaceutical use.


Luxembourg, October 2, 2018 – C2 PHARMA (Hall 6, Booth 6F40) has
announced a major expansion of its R&D program to grow its API portfolio at
CPhI 2018 in Madrid. The R&D program covers synthetic APIs as well as
naturally extracted APIs and botanicals for pharmaceutical use. The new
products are:

APIs under development:

  • Cannabidiol (CBD)
  • Atropine base
  • Hyoscyamine Sulfate
  • Hyoscyamine HBr
  • Tropicamide
  • Cyclopentolate HCl

APIs in feasibility stage:

  • Tetrahydrocannabinol (THC)
  • Thiocolchicoside
  • Colchicine
  • Yohimbine HCl
  • Dihydroergotamine

Botanical extracts under development:

  • Cannabis oil
  • Cannabis extract
  • Curcuma oil
  • Belladonna extract


C2 PHARMA is also launching a major initiative to bring a reliable source of
naturally extracted GMP-compliant cannabidiol (CBD) to the pharma industry:


  • The cultivation of cannabis will be fully compliant with Good Agricultural
    Practices (GAP) and follow a rigorous framework established and tested
    by C2 PHARMA to manage its partner-growers.
  • The extraction and manufacturing of pure Cannabidiol (CBD) will be based
    within the European Union and will use the latest purification techniques.
  • Samples will be available in first quarter of 2019, with commercial GMP
    quantities planned for the fourth quarter of 2019.

In parallel, C2 PHARMA is working on additional collaborations in the field of
cultivation, manufacturing and extraction technology as well as analytical
methods to meet the specific needs of the burgeoning cannabis industry as a
medicinal product in Europe and globally. Additional announcements are
expected in November 2018.

“We are taking the lead to develop the API and botanical extract solutions the
pharmaceutical industry will need to enable it to bring Cannabidiol (CBD) into an
incredibly broad range of therapeutic applications. Our involvement as a
specialist API manufacturer will provide pharmaceutical companies with the
credibility and reliability they need to run their programs,” said Andrew Badrot,
CEO of C2 PHARMA. “Whether you are exploring the entourage effect of
cannabis extracts or need the pure API, we will have a solution for you”.